• Explore /
  • Poster
  • / Saci-IO HR+: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1+ hormone receptor-positive (HR+) / HER2- metastatic breast cancer (MBC).

Saci-IO HR+: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1+ hormone receptor-positive (HR+) / HER2- metastatic breast cancer (MBC).

Abstract Poster

Authors

null

Ana Christina Garrido-Castro

Dana-Farber Cancer Institute, Boston, MA

Ana Christina Garrido-Castro , Tanya Elizabeth Keenan , Tianyu Li , Paulina Lange , Catherine Callahan , Jennifer Guerriero , Nabihah Tayob , Leilani Anderson , Daniel G. Stover , Keerthi Gogineni , Lisa A. Carey , Rita Nanda , Eric P. Winer , Elizabeth A. Mittendorf , Sara M. Tolaney

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT04448886

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS1102)

DOI

10.1200/JCO.2021.39.15_suppl.TPS1102

Abstract #

TPS1102

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Ana Christina Garrido-Castro

First Author: Sara M. Tolaney

First Author: Mark Chang

First Author: Farshid Dayyani